Baudax Stock Today

BXRX
 Stock
  

USD 0.71  0.01  1.39%   

Market Performance
0 of 100
Odds Of Distress
Less than 48
Baudax Bio is trading at 0.71 as of the 19th of August 2022; that is -1.39 percent decrease since the beginning of the trading day. The stock's open price was 0.72. Baudax Bio has 48 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Baudax Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of July 2022 and ending today, the 19th of August 2022. Click here to learn more.
CUSIP
07160F107
Fiscal Year End
December
IPO Date
22nd of November 2019
Category
Healthcare
ISIN
US07160F2065
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company was incorporated in 2019 and is based in Malvern, Pennsylvania. Baudax Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 6.42 M outstanding shares of which 101.82 K shares are currently shorted by private and institutional investors with about 1.26 trading days to cover. More on Baudax Bio
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Baudax Bio Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Baudax Bio's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Baudax Bio or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Baudax Bio generated a negative expected return over the last 90 days
Baudax Bio has some characteristics of a very speculative penny stock
Baudax Bio has high historical volatility and very poor performance
The company currently holds 8.71 M in liabilities with Debt to Equity (D/E) ratio of 2.06, implying the company greatly relies on financing operations through barrowing. Baudax Bio has a current ratio of 0.68, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Baudax Bio until it has trouble settling it off, either with new capital or with free cash flow. So, Baudax Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Baudax Bio sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Baudax to invest in growth at high rates of return. When we think about Baudax Bio's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 1.4 M. Net Loss for the year was (10.29 M) with loss before overhead, payroll, taxes, and interest of (1.36 M).
Baudax Bio currently holds about 5.21 M in cash with (45.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.65.
Baudax Bio has a frail financial position based on the latest SEC disclosures
Thematic IdeaHealthcare (view all)
Fama & French Classification
Average Analyst Recommendation
Analysts covering Baudax Bio report their recommendations after researching Baudax Bio's financial statements, talking to executives and customers, or listening in on Baudax Bio's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Baudax Bio. The Baudax consensus assessment is calculated by taking the average forecast from all of the analysts covering Baudax Bio.
Strong Buy3 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Baudax Bio based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Baudax Bio financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares2.4 M2.2 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted2.4 M2.2 M
Significantly Up
Increasing
Slightly volatile
Total Assets56.3 M53.3 M
Notably Up
Increasing
Slightly volatile
Total Liabilities54.2 M40.1 M
Significantly Up
Decreasing
Slightly volatile
Current Assets22.2 M23.5 M
Notably Down
Increasing
Slightly volatile
Current Liabilities17.4 M15.6 M
Moderately Up
Decreasing
Slightly volatile
Total Debt8.1 M8.5 M
Notably Down
Increasing
Slightly volatile
Asset Turnover0.01510.016
Notably Down
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Baudax Bio's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellUndervalued
Financial Strength
Baudax Bio's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Baudax Bio's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Baudax Bio's financial leverage. It provides some insight into what part of Baudax Bio's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Baudax Bio's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Baudax Bio deploys its capital and how much of that capital is borrowed.
Liquidity
Baudax Bio cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 8.71 M in liabilities with Debt to Equity (D/E) ratio of 2.06, implying the company greatly relies on financing operations through barrowing. Baudax Bio has a current ratio of 0.68, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Baudax Bio until it has trouble settling it off, either with new capital or with free cash flow. So, Baudax Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Baudax Bio sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Baudax to invest in growth at high rates of return. When we think about Baudax Bio's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(53.16 Million)
Baudax Bio (BXRX) is traded on NASDAQ Exchange in USA. It is located in 490 Lapp Road and employs 80 people. Baudax Bio is listed under Healthcare category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with current market capitalization of 6.04 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Baudax Bio's market, we take the total number of its shares issued and multiply it by Baudax Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Baudax Bio conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 6.42 M outstanding shares of which 101.82 K shares are currently shorted by private and institutional investors with about 1.26 trading days to cover. Baudax Bio currently holds about 5.21 M in cash with (45.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.65.
Check Baudax Bio Probability Of Bankruptcy
Ownership
Baudax Bio shows 3.43 percent if its outstanding shares held by insiders and 3.43 percent owned by other corporate entities .

Ownership Allocation (%)

Check Baudax Ownership Details

Baudax Stock Price Odds Analysis

What are Baudax Bio's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Baudax Bio jumping above the current price in 90 days from now is about 72.09%. The Baudax Bio probability density function shows the probability of Baudax Bio stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.3913 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Baudax Bio will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Baudax Bio is significantly underperforming DOW.
  Odds Below 0.73HorizonTargetOdds Above 0.73
27.80%90 days
 0.73 
72.09%
Based on a normal probability distribution, the odds of Baudax Bio to move above the current price in 90 days from now is about 72.09 (This Baudax Bio probability density function shows the probability of Baudax Stock to fall within a particular range of prices over 90 days) .

Baudax Bio Historical Income Statement

Baudax Bio Income Statement is one of the three primary financial statements used for reporting Baudax's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Baudax Bio revenue and expense. Baudax Bio Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Research and Development Expense is likely to rise to about 3.2 M in 2022, whereas Consolidated Income is likely to drop (21.3 M) in 2022. View More Fundamentals

Baudax Stock Against Markets

Picking the right benchmark for Baudax Bio stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Baudax Bio stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Baudax Bio is critical whether you are bullish or bearish towards Baudax Bio at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Baudax Bio without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Stock Screener Now

   

Stock Screener

Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
All  Next Launch Module

Invested in Baudax Bio?

You need to understand the risk of investing before taking a position in Baudax Bio. The danger of trading Baudax Bio is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Baudax Bio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Baudax Bio. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Baudax Bio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. Note that the Baudax Bio information on this page should be used as a complementary analysis to other Baudax Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Baudax Stock analysis

When running Baudax Bio price analysis, check to measure Baudax Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Baudax Bio is operating at the current time. Most of Baudax Bio's value examination focuses on studying past and present price action to predict the probability of Baudax Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Baudax Bio's price. Additionally, you may evaluate how the addition of Baudax Bio to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Is Baudax Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Baudax Bio. If investors know Baudax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Baudax Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.8 M
Quarterly Revenue Growth YOY
0.49
Return On Assets
-0.52
Return On Equity
-3.58
The market value of Baudax Bio is measured differently than its book value, which is the value of Baudax that is recorded on the company's balance sheet. Investors also form their own opinion of Baudax Bio's value that differs from its market value or its book value, called intrinsic value, which is Baudax Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Baudax Bio's market value can be influenced by many factors that don't directly affect Baudax Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Baudax Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Baudax Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Baudax Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.